Advanced Search

    Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    A 20.75 -4.42% -0.96
    ICPT closed down 4.42 percent on Wednesday, February 8, 2023, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Feb 28
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ICPT trend table...
    Date Alert Name Type % Chg
    New 52 Week High Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    New 52 Week Closing High Bullish -4.42%
    Pocket Pivot Bullish Swing Setup -4.42%
    New 52 Week High Strength -4.42%
    Upper Bollinger Band Walk Strength -4.42%
    Wide Bands Range Expansion -4.42%
    Older End-of-Day Signals for ICPT ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 3% about 11 hours ago
    Down 2 % about 13 hours ago
    60 Minute Opening Range Breakdown about 13 hours ago
    Rose Above Previous Day's High about 14 hours ago
    New 52 Week High about 14 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators Basic chart:

    Profile

    Intercept Pharmaceuticals, Inc. Description

    Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Diarrhea Liver Disease Hepatology Fibrosis Digestive Diseases Bile Acid Chronic Liver Disease Chronic Liver Diseases Primary Biliary Cholangitis Cirrhosis Farnesoid X Receptor Fxr Obeticholic Acid

    Is ICPT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 25 Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
    Jan 25 Intercept Pharma gains after patent settlement with Amneal
    Jan 24 Intercept: Huge Potential Upsides With Binary Catalyst Unlocking
    Jan 20 Intercept: FDA Accepts Application For Ocaliva In NASH
    Jan 20 Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?
    Jan 20 Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
    Jan 19 Intercept gains as NASH candidate goes under FDA review
    Jan 19 FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
    Jan 13 Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
    Jan 11 Intercept sees $343M adj. net sales in 2022
    See more ICPT news...

    Indicators

    Indicator Value
    52 Week High 21.86
    52 Week Low 10.81
    Average Volume 788,553
    200-Day Moving Average 15.49
    50-Day Moving Average 15.36
    20-Day Moving Average 17.74
    10-Day Moving Average 19.30
    Average True Range 1.01
    RSI 70.41
    ADX 42.32
    +DI 39.93
    -DI 7.52
    Chandelier Exit (Long, 3 ATRs) 18.83
    Chandelier Exit (Short, 3 ATRs) 17.09
    Upper Bollinger Bands 21.52
    Lower Bollinger Band 13.96
    Percent B (%b) 0.9
    BandWidth 42.62
    MACD Line 1.60
    MACD Signal Line 1.27
    MACD Histogram 0.3304
    Fundamentals Value
    Market Cap 684.59 Million
    Num Shares 33 Million
    EPS -10.44
    Price-to-Earnings (P/E) Ratio -1.99
    Price-to-Sales 3.90
    Price-to-Book 44.19
    PEG Ratio -0.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.42
    Resistance 3 (R3) 22.60 22.23 22.14
    Resistance 2 (R2) 22.23 21.81 22.14 22.04
    Resistance 1 (R1) 21.49 21.54 21.31 21.31 21.95
    Pivot Point 21.12 21.12 21.03 21.03 21.12
    Support 1 (S1) 20.38 20.70 20.20 20.20 19.55
    Support 2 (S2) 20.01 20.43 19.92 19.46
    Support 3 (S3) 19.27 20.01 19.36
    Support 4 (S4) 19.09